<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04179695</url>
  </required_header>
  <id_info>
    <org_study_id>2018_74</org_study_id>
    <secondary_id>2019-A01008-49</secondary_id>
    <nct_id>NCT04179695</nct_id>
  </id_info>
  <brief_title>Evaluation of a New Communication Aid Tool to Favor Global Patient Centered Care</brief_title>
  <acronym>PARKINSUN</acronym>
  <official_title>Optimizing PD Patient's Health Pathways: Favoring Global, Patient Centered Care by a New Communication Aid Tool PARKINSUN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Expert center of Parkinsonâ€™s Disease (CHU Lille)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>College of teaching general practitioners (CEMG Lille)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regional Health Agency (ARS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Orkyn'</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PARKINSUN is a new communication aid tool, expected to favor global patient centered care for
      PD patients during consultation with GPs and neurologists. Two groups of patients will be
      randomized to use or not PARKINSUN when they consult their physicians every 3 months during 7
      months.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>variation of the delta of G-MISS Questionnaire</measure>
    <time_frame>at 7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>G-MISS-Questionnaire at the end of each consultation (1 month, 4 months and 7 months)</measure>
    <time_frame>at the end of each consultation (1 month and 7 months)</time_frame>
    <description>Patient's satisfaction will be assessed by the G-MISS-Questionnaire. The G-MISS questionnaire is a standardized and validated tool in French. This questionnaire is taken from the American MISS-21 questionnaire, already used in neurologists to measure the satisfaction of patients with PD, after consultation It is easy to use with an average filling time of 6 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global score of PARKINSUN</measure>
    <time_frame>at the end of each consultation ((1 month and 7 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individuals scores of PARKINSUN</measure>
    <time_frame>at the end of each consultation ((1 month and 7 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDS-UPDRS scores</measure>
    <time_frame>at the end of each consultation ((1 month and 7 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PDQ-39 scores 6. Interpersonal Reactivity Index (IRI)</measure>
    <time_frame>at the end of each consultation ((1 month and 7 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Likert Scale</measure>
    <time_frame>at the end of each consultation (1 month and 7 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interpersonal Reactivity Index (IRI)</measure>
    <time_frame>at the end of each consultation (1 month and 7 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>consultation with Parkinsun</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>consultation as usual without Parkinsun</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Consulting with PARKINSUN as communication aid-tool</intervention_name>
    <description>Participating patients visit their general practitioner or neurologist with PARKINSUN at 1 months, 4 months, 7 months</description>
    <arm_group_label>consultation with Parkinsun</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Consulting without PARKINSUN as communication aid-tool</intervention_name>
    <description>Participating patients visit their general practitioner or neurologist without PARKINSUN at 1 months, 4 months, 7 months</description>
    <arm_group_label>consultation as usual without Parkinsun</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult men and women with all stages of PD

          -  Without severe chronic neurological or mental or psychiatric pathology

          -  Absence of cognitive impairment affecting autonomy (MDS criteria of dementia and MOCA
             &gt; 22)

          -  able to come (alone or accompanied) to consultation

          -  Affiliate or beneficiary of a social security scheme

          -  Subject having signed informed consent

          -  Patient willing to comply with all procedures of the study and its duration

        Exclusion Criteria:

          -  Administrative reasons: impossibility of receiving informed information, inability to
             participate in the whole study, absence of coverage by the social security system,
             refusal to sign consent.

          -  Subject under tutelage or curtailer.

          -  Subject not fluent in the French language to understand the instructions necessary to
             carry out the cognitive tests.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Devos</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Devos, MD,PhD</last_name>
    <phone>03 20 44 54 49</phone>
    <phone_ext>+33</phone_ext>
    <email>david.devos@chru-lille.fr</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Health pathway</keyword>
  <keyword>patient centered care</keyword>
  <keyword>communication aid- tool</keyword>
  <keyword>primary care</keyword>
  <keyword>secondary care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

